Humana‘s Medicare Advantage star Rating Lawsuit Dismissed: What It Means for You
A recent ruling in the Texas Northern District Court has sided with the centers for Medicare & Medicaid Services (CMS) in its dispute with Humana over Medicare Advantage (MA) star ratings. This decision has important implications for Humana, its members, and the broader landscape of the privatized Medicare program. as a seasoned healthcare analyst, I’ll break down what happened, why it matters, and what you can expect moving forward.
The Core of the Dispute: Interpreter Availability & Star Ratings
The CMS assigns star ratings – from 1 to 5 – to Medicare advantage plans based on a variety of quality metrics. These ratings aren’t just for show. They directly impact plan bonuses and, crucially, your ability to choose a high-performing plan.
One key metric assesses weather insurers provide timely access to foreign language interpreters for beneficiaries who need them. The CMS tests this by making “secret shopper” calls requiring translation services. Humana challenged a 3.5-star rating stemming from three unsuccessful interpreter availability tests at one of its call centers.
Humana argued the CMS’s methodology was unfair, specifically that the agency didn’t allow the call center to call back the test caller. They claimed this made the ratings arbitrary and capricious.
A Two-Round Legal Battle & The Court’s decision
This wasn’t a simple case. Here’s a timeline:
* Initial Dismissal (July): The court initially dismissed Humana’s first lawsuit because the insurer hadn’t fully exhausted its administrative appeals process with the CMS.
* Refiling & Renewed Challenge: After the CMS upheld its ratings, Humana refiled the lawsuit.
* Final Ruling (Tuesday): Judge Reed O’Connor ultimately ruled in favor of the CMS, upholding the legality of its “no-callback” policy. The case was dismissed with prejudice, meaning it can’t be refiled – though an appeal remains possible.
The judge determined the CMS’s policy isn’t arbitrary. Essentially, the court agreed that the agency is entitled to assess performance based on the initial interaction, even if a callback could have resolved the issue.
What Does This Mean for Humana?
The financial impact for Humana could be considerable. Analysts estimate a potential revenue loss of over $1 billion next year. Star ratings are directly tied to financial bonuses and a competitive edge in attracting members.
Here’s a breakdown of the impact:
* Reduced Revenue: Lower star ratings translate to reduced bonus payments from the CMS.
* Competitive Disadvantage: Plans with lower ratings may be less attractive to potential members.
* Shrinking Margins: Humana,already facing pressure on margins in the MA program,will feel this impact acutely.
* Falling Star Ratings: The percentage of Humana members in 4-star or higher rated plans has already dropped from 25% to 20% for 2026.
Humana has expressed disappointment and is considering its legal options, including an appeal. Though, the company proactively prepared for a potential loss, submitting bids for 2026 plans assuming an unfavorable outcome.
What Does This Mean for You as a Medicare Beneficiary?
This ruling underscores the importance of star ratings when choosing a Medicare Advantage plan. Here’s what you shoudl do:
* Prioritize 4-Star & 5-Star Plans: These plans often offer enhanced benefits and lower out-of-pocket costs.
* Consider Language Access: If you or someone you’re helping requires interpreter services, carefully research a plan’s language access capabilities.
* Don’t Rely Solely on Ratings: Star ratings are a valuable tool, but also consider your individual healthcare needs and preferences.
* Review CMS Data: The CMS provides detailed information on plan performance. Utilize this resource to make informed decisions: https://www.medicare.gov/plan-compare/
The Bigger Picture: A String of Challenges for Humana
This ruling is the latest in a series of headwinds for Humana. The company, the second-largest provider in the MA market with 5.8 million members,is navigating a challenging surroundings of shrinking margins and increased regulatory scrutiny.
Related reading